Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Other Working Capital Changes (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Other Working Capital Changes for 13 consecutive years, with -$1.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes rose 78.45% to -$1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $34.0 million, a 219.84% increase, with the full-year FY2025 number at $34.0 million, up 219.84% from a year prior.
  • Other Working Capital Changes was -$1.5 million for Q4 2025 at Madrigal Pharmaceuticals, up from -$9.3 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $35.4 million in Q2 2025 to a low of -$9.3 million in Q3 2025.
  • A 5-year average of $2.3 million and a median of $480000.0 in 2023 define the central range for Other Working Capital Changes.
  • Biggest YoY gain for Other Working Capital Changes was 10096.61% in 2024; the steepest drop was 22209.38% in 2024.
  • Madrigal Pharmaceuticals' Other Working Capital Changes stood at -$2.5 million in 2021, then surged by 46.44% to -$1.3 million in 2022, then surged by 102.42% to $32000.0 in 2023, then plummeted by 22209.38% to -$7.1 million in 2024, then surged by 78.45% to -$1.5 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Other Working Capital Changes are -$1.5 million (Q4 2025), -$9.3 million (Q3 2025), and $35.4 million (Q2 2025).